Influence of telmisartan on insulin response after glucose loading in obese patients with hypertension: Arb trial of hypertension in obese patients with hyperinsulinemia assessed by oral glucose tolerance test (ATHLETE)

Advances in Therapy

Volumn 28, Issue 8, 2011, Pages 698-706

  Mori, Yutaka ^a,b   Tanaka, Takaaki ^b   Matsuura, Kenichi ^a   Yokoyama, Junichi ^a   Utsunomiya, Kazunori ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Kawachi gun   (Japan)

Author keywords

Hypertension; Insulin resistance; Obesity; Oral glucose tolerance test; PPAR gamma activation; Telmisartan

Indexed keywords

ANTIHYPERTENSIVE AGENT; CANDESARTAN; CHOLESTEROL; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TELMISARTAN; TRIACYLGLYCEROL; VALSARTAN;

ABSENCE OF SIDE EFFECTS; AGED; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GLUCOSE TOLERANCE; HEMOGLOBIN BLOOD LEVEL; HOMEOSTASIS; HUMAN; HYPERINSULINEMIA; HYPERTENSION; INSULIN RESISTANCE; INSULIN RESPONSE; MALE; OBESITY; ORAL GLUCOSE TOLERANCE TEST; OUTCOME ASSESSMENT; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BENZOATES; BLOOD GLUCOSE; BLOOD PRESSURE; FEMALE; GLUCOSE; GLUCOSE TOLERANCE TEST; HUMANS; HYPERINSULINISM; HYPERTENSION; INSULIN RESISTANCE; MALE; OBESITY; TETRAZOLES; VALINE;

EID: 82455208899     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-011-0040-2     Document Type: Article

References (28)

1. Gallagher EJ, LeRoith D, Karnieli E. Insulinresistance in obesity as the underlying cause for themetabolic syndrome. Mt Sinai J Med. 2010;77:511-523.
2. Addison S, Stas S, Hayden MR, Sowers J. Insulinresistance and blood pressure. Curr Hypertens Rep.2008;10:319-325.
3. Chapman MJ, Sposito AC. Hypertension anddyslipidaemia in obesity and insulin resistance:pathophysiology, impact on atheroscleroticdisease and pharmacotherapy. Pharmacol Ther.2008;117:354-373.
4. Julius S, Kjeldsen SE, Weber M., et al. VALUE trialgroup. Outcomes in hypertensive patients at highcardiovascular risk treated with regimens based onvalsartan or amlodipine: The VALUE randomisedtrial. Lancet. 2004;363:2022-2231.
5. Ogihara T, Nakao K, Fukui T., et al. Effects ofcandesartan compared with amlodipine inhypertensive patients with high cardiovascularrisks: Candesartan Antihypertensive SurvivalEvaluation in Japan trial. Hypertension.2008;51:393- 398. (Pubitemid 351159955)
6. The ALLHAT Officers and Coordinators for theALLHAT Collaborative Research Group. Majoroutcomes in high-risk hypertensive patientsrandomized to angiotensin-converting enzymeinhibitor or calcium channel blocker vs diuretic:the Antihypertensive and Lipid-LoweringTreatment to Prevent Heart Attack Trial (ALLHAT).JAMA. 2002;288:2981-2997.
7. Kurtz TW, Klein U. Next generationmultifunctional angiotensin receptor blockers.Hypertens Res. 2009;32:826-834.
8. Benson SC, Pershadsingh HA, Ho C.I., et al.Hypertension: Identification of telmisartan as aunique angiotensin II receptor antagonist withselective PPAR?-modulating activity. Hypertension.2004;43:993-1002. (Pubitemid 38579904)
9. Honjo S, Nichi Y, Wada Y, Hamamoto Y, KoshiyamaH. Possible beneficial effect of telmisartan onglycemic control in diabetic subjects. DiabetesCare. 2005;28:498. (Pubitemid 40170973)
10. Vitale C, Mercuro G, Castiglioni C., et al. Metaboliceffect of telmisartan and losartan in hypertensivepatients with metabolic syndrome. CardiovascDiabetol. 2005;4:6.
11. Shimabukuro M, Tanaka H, Shimabukuro T. Effectsof telmisartan on fat distribution in individualswith the metabolic syndrome. J Hypertens.2007;25 841-848. (Pubitemid 46398879)
12. Davis TME. Ethnic diversity in type 2 diabetes.Diabet Med. 2008;25(suppl. 2):52-56. (Pubitemid 352020095)
13. Takeuchi M, Okamoto K, Takagi T, Ishii H. Ethnicdifference in patients with type 2 diabetes mellitusin inter-East Asian populations: A systematic reviewand meta-analysis focusing on fasting seruminsulin. Diabetes Res Clin Pract. 2008;81:370-376.
14. Examination Committee of Criteria for "ObesityDisease" in Japan, Japan Society for the Study ofObesity. New criteria for "obesity disease" in Japan.Circ J. 2002;66:987-992.
15. Ohnishi H, Saitoh S, Takagi S., et al. Incidenceof insulin resistance in obese subjects in a ruralJapanese population: The Tanno and Sobetsu study.Diabetes Obes Metab. 2005; 7: 83-87.
16. Japan Diabetes Society. Treatment Guide forDiabetes 2007. Tokyo: Bunkodo Co. Ltd.
17. Fogari R, Zoppi A, Ferrari I., et al. Comparativeeffects of telmisartan and eprosartan on insulinsensitivity in the treatment of overweighthypertensive patients. Horm Metab Res.2009;41:893-898.
18. Wulan SN, Westerterp KR, Plasqui G. Ethnic differences in body composition and the associatedmetabolic profile: A comparative study betweenAsians and Caucasians. Maturitas. 2010;65:315-319.
19. De Luis DA, Conde R, González-Sagrado M., et al.Effects of telmisartan vs olmesartan on metabolicparameters, insulin resistance and adipocytokinesin hypertensive obese patients. Nutr Hosp.2010;25:275-279.
20. Lacourcière Y, Krzesinski JM, White WB, Davidai G,Schumacher H. Sustained antihypertensive activityof telmisartan compared with valsartan. BloodPress Monit. 2004;9:203-210. (Pubitemid 39159163)
21. The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events.N Engl J Med. 2008;358:1547-1559.
22. US Food and Drug Administration web site.Micardis® (telmisartan) cardiovascular andrenal drugs advisory committee briefingdocument. July 29, 2009. Available at: Http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/ UCM173529.pdf. Accessed February 2011.
23. European Medicines Agency web site. Assessmentreport for Micardis. November 23, 2009. Availableat: Http://www.ema.europa.eu/docs/en-GB/document- library/EPAR-Assessment-Report-Variation/human/000209/WC500073444.pdf.Accessed February 2011.
24. Nakagami H, Morishita R. Obesity andgastrointestinal hormones-dual effect ofangiotensin II receptor blockade and a partialagonist of PPAR-?. Curr Vasc Pharmacol.2011;9:162-166.
25. Nakagami H, Kiomy Osako M, Nakagami.F., et al. Prevention and regression of non-alcoholic steatohepatitis (NASH) in a rat modelby metabosartan, telmisartan. Int J Mol Med.2010;26:477-481.
26. The Telmisartan Randomised AssessmeNt Studyin ACE iNtolerant subjects with CardiovascularDisease (TRANSCEND) Investigators. Effects ofthe angiotensin-receptor blocker telmisartanon cardiovascular events in high-risk patientsintolerant to angiotensin-converting enzymeinhibitors: A randomised controlled trial. Lancet.2008;372:1174-1183.
27. Teo K, Yusuf S, Sleight P., et al. Rationale, design,and baseline characteristics of 2 large, simple,randomized trials evaluating telmisartan, ramipril,and their combination in high-risk patients: TheOngoing Telmisartan Alone and in Combinationwith Ramipril Global Endpoint Trial/ TelmisartanRandomized Assessment Study in ACE IntolerantSubjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J. 2004;148:52-61. (Pubitemid 38906646)
28. The NAVIGATOR Study Group. Effect of valsartanon the incidence of diabetes and cardiovascularevents. N Engl J Med. 2010;362:1477-1490.